Information For Authors

Journal of Pancreatic Cancer Instructions for Authors


Journal of Pancreatic Cancer is an international, open access journal covering the clinical, translational and basic science of malignancies of the pancreas and the biliary region. Original research articles, review articles, narrative reviews, technical innovations, rapid communications, case reports, perspectives, and editorials covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, complementary and alternative treatment modalities and outcomes of pancreatic cancer are welcomed. The Journal considers high-quality clinical research letters for publication.

All manuscripts must be submitted through our online peer review submission system. Please be sure to read through the Instructions for Authors prior to submitting your paper.




Manuscripts should be submitted with the understanding that they have neither been previously published, nor are under simultaneous consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described as a footnote to the title.  By submitting a manuscript to Journal of Pancreatic Cancer, the author(s) agree(s) to each of these conditions.



All investigators who are engaged in research, regardless of funding, must comply with their institutions’ Internal Review Board procedures as well as federal regulations regarding the protection of human subjects.  Compliance must be indicated in the cover letter at the time of submission (see the Manuscript Preparation sections for cover letter requirements).  For further information, also see the Study Design and Ethics paragraph under the Publication Ethics and Malpractice Statement, below.



Journal of Pancreatic Cancer is a single-blind peer-reviewed journal.  All submissions to Journal of Pancreatic Cancer are subject to peer review.  Authors are encouraged, but not required, to supply the names and valid email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors prefer not be selected as a reviewer. However, reviewer selection is ultimately at the discretion of the Editor.


Use of English Language

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Journal of Pancreatic Cancer.  For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage.  The Publisher offers this service, with a subsidy from the author, prior to official submission (Contact for more information).  It is important to note that employing the use of the Publisher’s service, or any other editing service, does not guarantee acceptance of any paper. 


Article Publication Charges (APCs)

Journal of Pancreatic Cancer is a fully open access journal. The cost of maintaining and publishing the journal are covered by Article Processing Charges (APC). Visit the Journal’s Open Access Policy tab on our website (listed at the end of this paragraph) for more information about the journal’s APC. There is no cost for color figures, and there are no manuscript submission fees for this journal.


All submitted manuscripts will be processed through iThenticate, a plagiarism detection software. Plagiarized manuscripts will be rejected immediately.



All authors are encouraged to complete their submissions using an ORCID identifier.  Please visit the ORCID website for more information, or to register.


Permissions and Reprints

Journal of Pancreatic Cancer publishes articles under the Creative Commons (CC-BY) Attribution license. Users can read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without requesting prior permission from the Publisher or the author.

 Mary Ann Liebert, Inc., offers a reprint service for those who require professionally produced copies of a CC-BY licensed article. Contact: to obtain a price quotation. Please include the article DOI, title, number of reprint copies, and delivery destination in your request.


Open Access and Copyright

All articles published in Journal of Pancreatic Cancer are made freely and permanently accessible online upon publication without access or subscription charges, embargo periods, or user registration.

Upon submitting a manuscript for publication, the author(s) will agree to a Copyright and Open Access Licensing Agreement. Authors of articles published in the Journal will be the copyright holders and a Creative Commons CC-BY license will be applied. For more information, please read the full Creative Commons CC BY license.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, Liebert Open Access can accommodate non-standard copyright. Please contact: for more details.


Archiving and Preservation

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Journal of Pancreatic Cancer is fully NIH-, HHMI-, and Wellcome Trust-compliant.  Your article will be free online at, and will be easily searchable on Google, Google Scholar, and other search engines.


Please read all the instructions to authors before submitting.




Manuscripts must be submitted using the following URL:

Create an Account in Manuscript Central

All authors on a submitted manuscript must have a Manuscript Central account for Journal of Pancreatic Cancer. If any listed author on a submission does not already have an account in Manuscript Central for the journal, one will need to be created. Once you create your account, you may log in to the system to begin your submission.

Keywords (Areas of Expertise)

To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript.   These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.


Cover Letter
All submissions should include a cover letter from the corresponding author at the time of submission. The cover letter should include the following:

  • A declaration that the submission has received all authors’ Internal Review Board (IRB) approvals, if applicable.  If IRB approval has been waived, state the reason for exemption in the cover letter.
  • A statement detailing each listed author’s role to the development of the paper (see the Authorship paragraph* below for detailed information).
  • A statement indicating that the article has not been previously published in any form (except an abstract)
  • A statement confirming that the article is not under simultaneous consideration or in press elsewhere
  • Authors are encouraged to detail the significance and uniqueness of the work in a single paragraph
  • If non-preferred reviewers are selected, please state the reason for exclusion.



Authorship should be determined at the time of submission. Ensure the author listing is complete and all names are spelled correctly.  As defined by the International Committee of Medical Journal Editors (ICJME), authorship is based on the following criteria:

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  2. Drafting the work or revising it critically for important intellectual content; AND
  3. Final approval of the version to be published; AND
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding Author

It is the Journal’s policy that a submission carries only ONE corresponding author.  This designation should be determined at the time of submission.  All communications, except for individual copyright forms, will be managed through the corresponding author.

 Acknowledgment of Non-Qualifying Contributors

Contributors who do not meet all four (4) of the criteria for authorship should not be listed as authors, but they may be recognized in an Acknowledgment section. Some examples of activities that alone (without other contributions) do not qualify for authorship are: 

  •  Acquisition of funding;
  • General supervision of a research group or general administrative support;
  • Writing assistance, technical editing, language editing, and proofreading.

Those whose contributions do not justify authorship may be acknowledged individually or together as a group under the heading, Acknowledgments, and should be included in at the end of the manuscript before the Author Disclosure Statement(s).


Submitting Author/Agent

 It is incumbent upon the submitting author/agent to ensure the inclusion and accuracy of ALL contributing authors’ names, valid email addresses, and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship are generally not permitted.  Changes in authorship after publication are strictly prohibited.


Submissions should not exceed the limits for text, figures/tables, and references listed herein.

Article Type

Maximum Word Limit*

Abstract Word Limit





Original Articles


250 (structured)







300 (structured)





Narrative Review


300 (structured)





Technical Innovation


300 (unstructured)





Rapid Communication


100 (structured)





Case Report


200 (structured)



















Letter to the Editor







*These limits relate to the text of the manuscript; word limits do NOT include the title, authors, affiliations, abstract, headings, figure and/or table legends, acknowledgments, disclosures, or references.

*****Do not submit the manuscript or any of its components in PDF format.*****

Please continue reading for full requirements.


Original Articles:  Text must have a structured abstract, an introduction, and separate sections for Materials and Methods; Results; Discussion; and Conclusion.  Before the references, include an Acknowledgment section (if applicable), and an Author Disclosure Statement section (required).

Original Articles should include the following components:

  •  Title page (see section labeled Title Page for requirements)
  •  Structured Abstract: Purpose; Methods; Results; Conclusion (see word limit table above)
  •  Text: Introduction; Methods; Results; Discussion; Conclusion; Acknowledgments, Disclosure(s)
  •  References (in proper journal format; see Reference Style section below)
  •  Figure Legends (if applicable)
  •  Tables and table titles (if applicable)

Review Articles
 (quantitative, narrative, and qualitative reviews):  The Journal recommends that you use the following headings to conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (title, abstract, methods, results, discussion, conclusion, acknowledgment, disclosures/funding, references). For more information, visit the PRISMA website.

Review Articles should include the following components:

  •  Title page (see section labeled Title Page for requirements) 
  •  Abstract (see word limit table above)
  •  Text: Introduction; Methods; Results; Discussion; Conclusion, Acknowledgments, Disclosure(s). Details on the study selection and inclusion process and on the participants in each selected study should be included
  •  References (in proper journal format; see Reference Style section below)
  •  Figure Legends (if applicable)
  •  Tables and table titles (if applicable)

Narrative (non-systematic) Reviews

Narrative Reviews should address a clinical, educational, or methodological problem by combining expert opinions with a thorough and balanced review of available evidence. Narrative reviews are appropriate when the question of interest is too broad, the body of evidence too sparse, or the topic is too new or controversial for a systematic review. Structurally, authors should begin narrative reviews with an illustrative case or example. The review should put the topic into the context of the literature and interpret the evidence to resolve the problem for the reader.  Narrative Review articles should include the same components as a Review Article, detailed above.

Technical Innovation

Technical innovations should present a new experimental or computational method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available.

Technical Innovations should include the following components:

  • Unstructured Abstract:  300 words or less
  • Introduction/Objective: Briefly state the condition or problem being addressed
  • Technology or Method: Briefly outline the technological innovation used to address the condition or situation.
  • Results: Discussion of the outcomes of the innovation.
  • Clinical Impact: Describe the translational aspect and its potential clinical impact of the technology or method presented in the manuscript.
  • Conclusions

Rapid Communications

Reports of particularly promising preliminary findings, or other research findings that are not suitable for a full Original Article.

 Rapid Communications should include the following components:

  •  Title Page (see section labeled Title Page for requirements)
  •  Abstract: Structured headings (Purpose; Methods; Results; Conclusion; see word limit table above).
  •  Text [Introduction; Methods; Results; Discussion; Conclusion; Acknowledgments, Disclosure(s)]
  •  References (in proper journal format; see Reference Style section below)
  •  Figure Legends (if applicable)
  •  Tables and table titles (if applicable)

Case Report

Case reports submitted to Journal of Pancreatic Cancer should contribute to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches.

Case reports should include relevant positive and negative findings from history, examination and investigation, and can include clinical photographs, provided these are accompanied by written consent to publish from the patient(s). Case reports should include an up-to-date review of all previous cases in the field.

Authors are encouraged to describe how the Case report is rare or unusual as well as its educational and/or scientific merits in the covering letter that will accompany the submission of the manuscript.

Authors should seek written and signed consent to publish the information from the patients or their guardians prior to submission.


Case reports should include the following components:

The abstract should not exceed 200 words. The abstract must include the following separate sections:

  • Background: Define novelty of presented case
  • Presentation: Describe the patient’s clinical details, diagnosis, and outcomes
  • Conclusions: Summarize the clinical impact or potential implications



Perspectives present opinions and insights on a current topic, describe novel hypotheses, or consider controversial issues, including legal, policy, and ethical issues. These articles may provide critical commentary on recent advances and future directions and discuss implications for clinical practice or public health. The perspective and points in the article should be supported by relevant literature.

 Perspectives should include the following components: 

  •  Title page
  •  Abstract: Structured headings are not required.
  •  Text: Introduction and a Conclusion are mandatory.
  •  References (in applicable; in proper journal format; see Reference Style section below)
  •  Figure Legends
  •  Tables and table titles (if applicable)

Letters to the Editor

Letters should include the following components:

  •  Title Page: Include a short title related to, but distinct from, the published article being addressed.
  •  Text
  •  References (if applicable; (in proper journal format; see Reference Style section below)
  •  Figure Legend (if applicable)
  •  Table and table title (if applicable)

Special Note: The Editors may choose to invite the authors to submit a response to the Letter.

Manuscript keywords (search terms): On the title page of the manuscript, enter a minimum of three (3), maximum of six (6), search terms that will aid in the discoverability of the article in indexing services and search engines.  These terms may or may not be different from the terms you select for the peer review process and areas of expertise. You will be asked to retype these search terms in the submission form when uploading your manuscript.  These keywords will be included in the published article.  If the search terms entered do not match the manuscript, the manuscript will serve as the default.


General Formatting and Style 

  •  Font: Times New Roman or Arial in 12-point type
  •  Abbreviations: Expand all abbreviations at first mention in the abstract, and then again at first mention     in the text. Use abbreviations thereafter.
  •  Page size: Letter size (8.5 x 11 inches)
  •  Margins: 1 inch
  • Line and word spacing: Double-space all manuscript pages, including figure legends.




  •  File names must be in English.
  •  Name figure files using only alphanumeric characters.  Do not use symbols, underscores, spaces, dots, or dashes.
  •  For figures, file names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1)

Title Page

The title (first) page of all manuscripts should be part of the full manuscript file and must contain the following information:

  •  Full manuscript title (No proprietary names, registered/trade names, or abbreviations should be within the manuscript title)
  •  All participating authors should be listed on the manuscript at the time of submission (see Authorship* criteria above).  Changes in authorship are generally not permitted after acceptance of an article, and are not permissible after publication.
  •  For each author, list:
    •         Full name, including middle initial if desired
    •         Primary academic degrees (such as MD, DO, PhD, MPH, etc. Do not list
              undergraduate or honorary degrees, fellowship or society memberships, etc.)
    •         Institutional affiliation(s), including institution, department, street address, city,
              and state, zip/postal code (and country if outside the United States.)
    •         Valid email address

Co-first authors are permitted, if desired. On the title page, include an asterisk after each co-first author and include a corresponding footnote. (Ex: These authors are considered first authors.  OR: These authors contributed equally to this work.)

  •  Running head: 50 characters or fewer (including spaces; abbreviations acceptable)
  •  Word Count/Number of items: Indicate abstract and main text word counts and number of tables, figures, and appendices (if applicable).

ABSTRACT (must be included within the main article file, after the title page)

  •  See Word Limits table above for requirements
  •  Do not use proprietary names, trade names, or references in the abstract.


  •  Must contain a statement about IRB approval, if applicable/required.

After the Conclusion of the main body of the manuscript, include a separate section acknowledging any contributors who did not meet the requirements for authorship and any science writers or corporate employees who participated in the development of the manuscript. Also include acknowledgments of research support for the study.

Author Disclosure Statement(s)

Following the Acknowledgments section (or Disclaimer if one was included), include a section entitled ‘‘Author Disclosure Statement.’’ Here authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscript. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’

Authors are responsible for the accuracy and completeness of their references. Number references in the order they are cited in the text; do not alphabetize. In-text citations should be in sequential numerical order, superscripted, not contained within parentheses or brackets, and placed after punctuation.

Begin the Reference section on a separate page after the Author Disclosure Statement section.

  •  Double-space all lines and single space between words
  •  Articles accepted and in press should be included in the Reference section
  •  Personal communications, unpublished data, or manuscripts “in preparation” or “submitted for consideration” should not be included in the Reference section. If necessary, these should be included at the appropriate place, in parentheses, in the body of the text. Personal communications should include the contact’s first initial and last name, and the month and year of the communication.
  •  List up to three (3) authors and/or editors; for 4 or more, list the first 3 followed by et al.
  •  For books, volume and edition numbers should be included when appropriate.
  •  Abbreviate journal titles in accordance with  PubMed / MEDLINE
  •  Do not include PMIDs or PCMIDs in references.
  •  References that are abstracts should be indicated as such, with the abstract number included, if applicable.
  •  Use DOI numbers only if the citation is from an online-only publication, or if final volume and/or pagination has not been assigned or is not available.

Reference Samples

Journal Article

Punctuation and order of elements:

Last name First/middle initial, (up to 3 names, then et al.).Title of article (capitalize only first letter of title). Journal abbreviation as per PubMed. Year;volume number:full inclusive page range.

Flores JP, Diasio RB, Saif MW.  Drug metabolism and pancreatic cancer.  Ann Gastroenterol. 2017;30:54-61.

Chapter in edited volume

Punctuation and order of elements:          

Last name First/Middle initial, (up to 3 names, then et al.). Title of chapter (capitalize only first letter of title).  In: Book Title (in italic; follow capitalization as it appears on the book cover). Last name First/Middle initials, (eds).  City of publisher: Name of publisher, year, pp. (inclusive page range). 

Thiede M, Akweongo P,  McIntyre D. Exploring the dimensions of access. In: The Economics of Journal of Pancreatic Cancer. Edited by McIntyre D, Mooney G.  Cambridge: Cambridge University Press, 2007, pp. 103-123.


Punctuation and order of elements:

Last name First/Middle initial(s).  Book Title (in italics; follow capitalization as it appears on the book cover).  City of publisher: Name of publisher, year.

Hardacre JM.  Pancreatic Cancer and Periampullary Neoplasms. Philadelphia: Elsevier, 2016.

Website (Sample):

National Cancer Institutes.  Cancer Currents: An NCI Cancer Research Blog.  Available at   Accessed January 5, 2017.

Within the text, cite tables in the order in which they appear using Arabic numerals. Tables in accepted articles will be typeset and placed near the first mention of the table in the text; do not include separate lines indicating table placement.

  •  Prepare all tables in one separate Word file (not as a PDF). 
  •  Tables should not be included in the main text file.
  •  Do not embed tables in the text where they are cited.
  •  Provide a brief but descriptive title for each table.
  •  Avoid abbreviations in the table title when possible.
  •  Table footnote(s) should include any essential notes and must include definitions of all abbreviations and acronyms used in the table.

Within the text, cite figures in the order in which they appear using Arabic numerals. Figures in accepted articles will be placed near the first mention of the figure in the text; do not include separate lines indicating figure placement.

  •  Do not prepare figures in Word.
  •  Each figure must be supplied in either .TIFF or .EPS format. 
  •  All figures must be submitted as separate files.  Do not embed figures within the main text file.
  •  Do not submit figures as PDFs, PowerPoint, or Excel files.
  •  Line illustrations should be submitted at a minimum of 600 DPI.  Halftones and color should be submitted at a minimum of 300 DPI.
  •  Color art should be saved as RGB.

Figure legends

After the Reference section of the article in the main Word document include a separate page with the following information for each figure:

  •  A brief but descriptive legend for each figure.  If figure is divided into multiple parts, each part should be defined in the legend.
  •  Define all relevant information in figures, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets.

Appendix and supplementary material guidelines

  •  Should be important to understanding or interpretation of the manuscript and limited in length
  •  Should be original and not previously published
  •  Acceptance of online-only materials is separate from acceptance of the manuscript and at the Editors’ discretion



Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.

Definitions of Scientific Misconduct

Mary Ann Liebert, Inc., publishers generally follow the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  •  Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
  •  Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  •  Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  •  Material failure to comply with legislative and regulatory requirements affecting research: 
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  •  Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  •  Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  •  Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
  •  Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.

Responding to Allegations of Possible Misconduct

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

Protection of Research Participants

Informed Consent, Study Ethics Approval, and Subject Confidentiality

All manuscripts must comply with the recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. For more information, visit The International Committee of Medical and Journal Editors.

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate. * In the Methods section of the article, authors must state that informed consent was obtained from subjects (specify written or verbal).

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, authors should provide assurance, and editors should so note, that such changes do not distort scientific meaning. *

 When reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed. *

*These sections of Journal of Pancreatic Cancer’s Instructions for Authors have been quoted directly from the International Committee of Medical Journal Editors website. For more information, visit

Post-Submission Information

Submission-Related Emails and Online Status
The Manuscript Central system sends emails only to the corresponding author (except for copyright/licensing release emails for accepted articles).

Manuscript Decisions
Manuscripts may receive decisions of Reject, Major Revision, Minor Revision, or Accept. A manuscript decision of Major Revision or Minor Revision does not guarantee the manuscript will ultimately be accepted. Article type word limits apply to revisions as well as initial submissions.


Authors are responsible for procuring any and all permissions to reproduce illustrations or tables taken from other publications and must be acknowledged by a complete credit line in the figure legend. The original publisher’s letter of permission should be available for submission to Journal of Pancreatic Cancer if requested by the Editors and/or the Publisher. A full citation should also be included in the Reference section.

Page Proofs

An email containing a link to the PDF file of the page proof is sent to the corresponding author from the email address  The page proofs should be read carefully and returned within three (3) business days to the Publisher with the author’s/authors’ approval or corrections.  The Publisher can only accept one set of corrections from the corresponding author. 



Journal of Pancreatic Cancer is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215, Tel: (914) 740-2100; Fax: (914) 740-2101; Email:;  Website:


Journal of Pancreatic Cancer is a journal of broad interest that has been launched to overcome unnecessary barriers to the immediate availability and use of research.

Benefits of publishing in Journal of Pancreatic Cancer:

  • High visibility, immediate and unrestricted online access to published articles
  • Rigorous peer review
  • Easy compliance with open access mandates
  • Authors retain copyright 
  • Highly indexed – citation tracking and inclusion in bibliographic databases
  • Targeted email marketing

The article publication charge foJournal of Pancreatic Cancer is $1,500.00 USD for accepted publications.

Copyright and Licensing
Journal of Pancreatic Cancer publishes articles under the liberal CC-BY license. This means that articles can be freely redistributed and reused by the author and others as long as the article is properly cited. Published articles in Journal of Pancreatic Cancer can be deposited immediately into an online repository or social network without an embargo. Journal of Pancreatic Cancer articles can be emailed to colleagues, printed, archived in a collection, included in course-packs, and distributed without restrictions. Please read the full Creative Commons license for further information.



Journal of Pancreatic Cancer is fully compliant with NIH-, HHMI-, Wellcome Trust-, RCUK-, and major funder open access policies.

Mary Ann Liebert, Inc. will deposit all NIH-funded articles published in Journal of Pancreatic Cancer to PubMed Central (PMC) upon online publication without an embargo period. Our workflow ensures compliance with the NIH Public Access Policy which mandates that NIH-funded authors submit their research article to PMC, or have their peer-reviewed author accepted manuscript submitted on their behalf, at point of acceptance by a journal.

Please note that PubMed Central, not the Publisher, has sole control over when the paper is made live on PMC.

Publishing in Open Access Journals

There are no archiving restrictions for open access articles published under creative commons licenses. Author manuscripts and the final published version of any article published in Journal of Pancreatic Cancer can be archived in a repository, preprint server, or shared on a research network without an embargo.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.